Lupin Acquires Sanofi Brands Aarane & Nalcrom

This move aligns with Lupin’s strategy to enhance its global presence in specialty areas, particularly respiratory and gastrointestinal care. 

Lupin Limited’s European unit, Lupin Atlantis Holdings SA, completed the acquisition of Aarane in Germany and Nalcrom in Canada and the Netherlands from Sanofi. 

This move aligns with Lupin’s strategy to enhance its global presence in specialty areas, particularly respiratory and gastrointestinal care. Additionally, Lupin secured the associated trademark rights for Aarane and Nalcrom as part of this acquisition. 

Dr Fabrice Egros, president of corporate development at Lupin, said, "This acquisition will strengthen our global position in treating patients suffering from diverse respiratory diseases and conditions. It adds accretive assets in gastrointestinal care that broaden our portfolio of branded products."

Strengthening the Respiratory Business

Lupin highlighted that acquiring these brands is a strategic step to boost its respiratory business in Germany. Aarane (sodium cromoglicate/reproterol hydrochloride pressurized inhalation) treats sudden asthma attacks and prevents exercise-induced asthma. 

The company expects Aarane to complement its existing respiratory products, such as LuforbecTM, which were introduced recently in the German market.

Nalcrom (sodium cromoglicate oral) is another significant addition to treating food allergies. This anti-allergic medication is essential for patients who have tested positive for specific allergens and need to avoid these allergens strictly. Both products are expected to bolster Lupin’s specialty pharmaceutical portfolio and provide robust treatment options for patients.

Other Noteworthy Developments

In a related development, Lupin Digital Health, a prominent player in the digital health sector, announced a significant achievement for its Lyfe platform. The platform secured approval as a Class C Medical Device from the Central Drugs Standard Control Organization (CDSCO). 

This approval marks a critical advancement in post-discharge integrated care, showcasing the potential of evidence-based digital therapeutic solutions to improve patient care.

In addition to the Class C Medical Device license for the Lyfe platform, Lupin Limited, the parent company, has launched Bromfenac Ophthalmic Solution, 0.075%, following the United States Food and Drug Administration (US FDA) approval. 

This solution serves as the generic counterpart to BromSite Ophthalmic Solution, 0.075%, produced by Sun Pharmaceutical Industries. It caters to postoperative inflammation and prevents ocular pain among patients undergoing cataract surgery.

Furthermore, Lupin Digital Health partnered with the American College of Cardiology (ACC) to launch the first-ever digital therapeutics certificate for cardiologists. This initiative recognizes cardiologists' commitment to innovation and patient-centered healthcare by adopting Lupin's Remote Cardiac Rehab and Digital Heart Failure clinic solutions.

Last year, Lupin introduced several patient engagement programs in the digital health space. 'Humrahi, a patient support program, focuses on helping patients manage diabetes, while Jeet promotes heart health by offering cost-effective medical solutions, disease counseling, medication reminders, and lifestyle guidance.